#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Hav­ing worked in par­al­lel for years to move their re­spec­tive PD-1 in­hibitors up to the first-line treat­ment of gas­troin­testi­nal can­cers, Mer­ck and Bris­tol My­ers Squibb fi­nal­ly have the da­ta at ES­MO for a show­down.

Com­par­ing KEYNOTE-590 and Check­Mate-649, of course, comes with the usu­al caveats. But a side-by-side look at the over­all sur­vival num­bers al­so of­fer some per­spec­tive on a new fron­tier for the reign­ing check­point ri­vals, both of whom are claim­ing to have achieved a first.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER